Serum sST2 levels and the proportions of the study participants that exceed the clinical cutoff 35 ng/mL
| Sex | No. of participants | Mean age±SD (yr) | sST2 (ng/mL) | No. of participants (%) >35 ng/mL | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.5th | 5th | 10th | 25th | 50th | 75th | 90th | 95th | 97.5th | ||||
| Males | 90 | 74.4±6.9 | 15.5 | 19.0 | 19.9 | 25.1 | 32.9 | 39.7 | 46.5 | 58.6 | 62.0 | 37 (41.1) |
| Females | 52 | 71.8±9.1 | 15.6 | 17.4 | 19.1 | 23.5 | 26.9 | 34.4 | 41.8 | 48.7 | 50.7 | 10 (19.2) |
Abbreviations: sST2, soluble suppression of tumorigenicity 2; SD, standard deviation.